For research use only. Not for therapeutic Use.
Isoformononetin-d3 is the deuterium labeled Isoformononetin (HY-N7501). Isoformononetin is an analog of Daidzein (HY-N0019) and has immunoprotective effects. Isoformononetin inhibits the differentiation of Th17 and B-cells lymphopoesis to promote osteogenesis in estrogen-deficient bone loss conditions[1][2].
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[2].
| Catalog Number | I041337 |
| Synonyms | 3-(4-hydroxyphenyl)-7-(trideuteriomethoxy)chromen-4-one |
| Molecular Formula | C16H9D3O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C16H12O4/c1-19-12-6-7-13-15(8-12)20-9-14(16(13)18)10-2-4-11(17)5-3-10/h2-9,17H,1H3/i1D3 |
| InChIKey | LNIQZRIHAMVRJA-FIBGUPNXSA-N |
| SMILES | COC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=C(C=C3)O |
| Reference | [1]. Mansoori MN, et al. Methoxyisoflavones formononetin and isoformononetin inhibit the differentiation of Th17 cells and B-cell lymphopoesis to promote osteogenesis in estrogen-deficient bone loss conditions. Menopause. 2016 May;23(5):565-76. [2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |
